Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 217% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 4/9 — moderate financial health
- ROE of 14.5% — below-average profitability
- Revenue growing at 11% annually
STRYKER CORP (SYK) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NYSE , with a market capitalisation of $128.5 billion . Key value metrics: P/E ratio 39.6, P/B ratio 6.61, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
STRYKER CORP — Fundamental Analysis Summary
STRYKER CORP (SYK) is currently trading 217% above its Graham Number of $105.79, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 39.6x.
On financial health, SYK shows a moderate Piotroski F-Score of 4/9, and modest return on equity of 14.5% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.66.
StockPik's composite Value Score for SYK is 40/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
SYK reports a high gross margin of 64.0% (sector average: 33.5%) and a solid operating margin of 16.6%.
SYK shows revenue growing at 11% year-over-year, with earnings growing at 8%.
SYK pays a modest dividend yield of 1.0%.